ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Amazon Explores AI Content Marketplace With Media Publishers 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
VANCOUVER, British Columbia, April 09, 2018 -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) today announced that it has secured DTC Eligibility for its common shares listed on the OTC market in the United States.
About the Depository Trust Company
The Depository Trust Company (DTC) is a subsidiary of the Depository Trust & Clearing Corporation DTCC and manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through the DTC are considered "DTC eligible." This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
“George Robinson”
Chief Executive Officer
For further information, please contact:
Mathieu McDonald, Corporate Communications – 604-484-1230
Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
